ORCHESTRA BIOMED HOLDINGS, INC. Financials Orchestra BioMed Holdings, Inc.
Equities
OBIO
US68572M1062
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.3 USD | +1.53% |
|
+1.73% | -41.95% |
| 05-13 | Earnings Flash (OBIO) ORCHESTRA BIOMED HOLDINGS Reports Q1 Revenue $620,000 | MT |
| 05-13 | Orchestra BioMed Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | - | - | 326.3 | 189.7 | - | - |
| Enterprise Value (EV) 1 | - | - | 326.3 | 189.7 | 189.7 | 189.7 |
| P/E ratio | -0.92 x | -0.68 x | -6.17 x | -3.31 x | -3.42 x | -3.84 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 118 x | 57.8 x | 48.9 x | 65.1 x |
| EV / Revenue | - | - | 118 x | 57.8 x | 48.9 x | 65.1 x |
| EV / EBITDA | - | - | -6.37 x | -3.01 x | -2.67 x | -3.21 x |
| EV / FCF | - | - | -7.06 x | -3.95 x | -3.72 x | -4.04 x |
| FCF Yield | - | - | -14.2% | -25.3% | -26.9% | -24.8% |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | - | - | 35,744 | 35,788 | - | - |
| Reference price 2 | 10.08 | 9.980 | 9.130 | 5.300 | 5.300 | 5.300 |
| Announcement Date | 22/11/22 | 24/03/23 | 27/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 3.533 | 2.76 | 3.28 | 3.876 | 2.913 |
| EBITDA 1 | - | - | -51.22 | -63 | -71 | -59 |
| EBIT 1 | - | -32.66 | -51.51 | -60.18 | -64.61 | -56.71 |
| Operating Margin | - | -924.34% | -1,866.16% | -1,834.79% | -1,667.19% | -1,946.82% |
| Earnings before Tax (EBT) 1 | - | -33.61 | -49.12 | -57.12 | -55.42 | -49.42 |
| Net income 1 | -23.01 | -35.62 | -49.12 | -57.12 | -55.42 | -49.42 |
| Net margin | - | -1,008.15% | -1,779.71% | -1,741.49% | -1,430.11% | -1,696.6% |
| EPS 2 | -10.90 | -14.60 | -1.480 | -1.600 | -1.550 | -1.380 |
| Free Cash Flow 1 | - | - | -46.2 | -48 | -51 | -47 |
| FCF margin | - | - | -1,674.09% | -1,463.41% | -1,315.96% | -1,613.46% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 22/11/22 | 24/03/23 | 27/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.103 | 1.164 | 0.915 | 0.419 | 0.262 | 0.62 | 0.906 | 0.863 | 0.891 | 0.635 | 0.726 |
| EBITDA 1 | - | - | - | - | -12.41 | -14.35 | -15.3 | -16.8 | -16 | - | - |
| EBIT 1 | -9.828 | -11.54 | -12.96 | -14.52 | -12.48 | -14.42 | -15.66 | -15.19 | -14.92 | -14.9 | -14.59 |
| Operating Margin | -891.02% | -991.84% | -1,415.96% | -3,466.35% | -4,763.74% | -2,326.29% | -1,728.04% | -1,759.68% | -1,674.07% | -2,347.24% | -2,009.92% |
| Earnings before Tax (EBT) 1 | -9.75 | -10.94 | -12.05 | -13.32 | -12.82 | -13.46 | -14.96 | -14.49 | -14.22 | -14.2 | -13.89 |
| Net income 1 | -9.75 | -10.94 | -12.05 | -13.32 | -12.82 | -13.46 | -14.96 | -14.49 | -14.22 | -14.2 | -13.89 |
| Net margin | -883.95% | -939.86% | -1,316.5% | -3,178.04% | -4,892.37% | -2,171.45% | -1,650.77% | -1,678.56% | -1,595.51% | -2,237.01% | -1,913.5% |
| EPS 2 | -3.880 | -0.4000 | -0.3500 | -0.3800 | -0.3700 | -0.3800 | -0.4200 | -0.4000 | -0.4000 | -0.4000 | -0.3900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 24/03/23 | 12/05/23 | 10/08/23 | 13/11/23 | 27/03/24 | 13/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -46.2 | -48 | -51 | -47 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | 0.08 | 1 | 1 | 1 |
| Capex / Sales | - | - | 2.83% | 30.49% | 25.8% | 34.33% |
| Announcement Date | 22/11/22 | 24/03/23 | 27/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.3
USD
Average target price
16.33
USD
Spread / Average Target
+208.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -41.95% | 190M | |
| +10.03% | 223B | |
| +13.59% | 195B | |
| +20.01% | 144B | |
| +30.83% | 111B | |
| +2.05% | 65.01B | |
| +15.38% | 53.02B | |
| +3.96% | 50.45B | |
| +8.37% | 44.15B | |
| +3.27% | 36.45B |
- Stock Market
- Equities
- OBIO Stock
- Financials Orchestra BioMed Holdings, Inc.
